 |
| |
 |
| |
 |
| |
 |
| |
 |
_____________________________________________________________________________________________________________________
© 2005-9 All Rights Reserved. NOD Pharmaceuticals, Inc.
SHANGHAI, Nov. 24 /PRNewswire-Asia/ -- NOD Pharmaceuticals Inc. announced that US &
Trademark Office (PTO) has allowed the patent application for its nano-particle oral delivery or
NOD technology.
NOD technology is a highly efficient approach to incorporate peptides or proteins into bio-adhesive
nano-particles to enable oral delivery of drugs otherwise administered as injections. NOD
technology is a platform technology that can be applied to many macromolecular drugs such as
insulin, interferon, growth hormone, exenatide, heparin and more.
Currently, an oral insulin formulation, the first candidate developed with NOD technology, is
entering phase I clinical studies in China.
"Patent allowance for NOD technology is a major step forward for NOD", quoted from William
Lee, CEO. "With this patent, and in combination with others, NOD is building a solid foundation for
its intellectual property and core competence.”
For more information, please contact:
William Lee, Ph.D., CEO
Phone: +86-21-6194-0758
Email: info@nodpharm.com
Notes for Editors
About NOD Pharmaceuticals
NOD Pharmaceuticals, Inc. is a development stage biotech company and emerging leader in
innovative delivery for biopharmaceuticals. NOD uses patented platform technology, nano-particle
oral delivery or NOD technology, to develop oral formulations for biopharmaceuticals, including
insulin, exenatide, interferon, human growth hormone and more.
More information can be found at http://www.nodpharm.com
SOURCE NOD Pharmaceuticals, Inc.
Trademark Office (PTO) has allowed the patent application for its nano-particle oral delivery or
NOD technology.
NOD technology is a highly efficient approach to incorporate peptides or proteins into bio-adhesive
nano-particles to enable oral delivery of drugs otherwise administered as injections. NOD
technology is a platform technology that can be applied to many macromolecular drugs such as
insulin, interferon, growth hormone, exenatide, heparin and more.
Currently, an oral insulin formulation, the first candidate developed with NOD technology, is
entering phase I clinical studies in China.
"Patent allowance for NOD technology is a major step forward for NOD", quoted from William
Lee, CEO. "With this patent, and in combination with others, NOD is building a solid foundation for
its intellectual property and core competence.”
For more information, please contact:
William Lee, Ph.D., CEO
Phone: +86-21-6194-0758
Email: info@nodpharm.com
Notes for Editors
About NOD Pharmaceuticals
NOD Pharmaceuticals, Inc. is a development stage biotech company and emerging leader in
innovative delivery for biopharmaceuticals. NOD uses patented platform technology, nano-particle
oral delivery or NOD technology, to develop oral formulations for biopharmaceuticals, including
insulin, exenatide, interferon, human growth hormone and more.
More information can be found at http://www.nodpharm.com
SOURCE NOD Pharmaceuticals, Inc.
Press Release
 |  |  |
| US Patent Allowed for NOD Tech |
NOD
Pharmaceuticals, Inc.
| Innovation Delivered |
| | |